medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Number 2

<< Back Next >>

Ann Hepatol 2008; 7 (2)

Genotyping of hepatitis C virus (HCV) in infected patients from Northeast MexicoGenotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico

Rivas-Estilla AM, Cordero-Pérez P, Trujillo-Murillo KC, Ramos-Jiménez J, Chen-López C, Garza-Rodríguez ML, Ramírez-Gutiérrez A, Muñoz-Espinosa L

Language: English
References: 19
Page: 144-147
PDF size: 118.48 Kb.


Text Extraction

Information about HCV genotypes in infected patients from different regions of Mexico is limited. Objective: To determine the prevalence of HCV genotypes in a group of HCV infected patients who attended a third level Hospital in Northeast of Mexico. Methods: Genotyping analysis was performed using the InnoLiPA-HCV genotype assay in 147 patients (65 males and 82 females, mean age 44 ± 12 years) with positive anti-HCV antibodies and detectable HCV-RNA levels. Results: Infected individuals were more likely to be female (56%). Histological data showed that 63% of the patients had chronic hepatitis, while the remainder presented cirrhosis (37%). The most frequent HCV genotype was 1 (73%). We found the following distribution: genotype 1 (2.7%), 1a (28.6%), 1b (37.4%), 1a/1b (4.1%), 2a (1.4%), 2b (8.8%), 2c (0.7%), 2a/2c (2.7%), 3 (2%), 3a (10.2%), 4 (0.7%) and 4c (0.7%). The most frequent associated risk factor was blood transfusion (72.5%). Conclusion: Prevalence of HCV genotypes in the Northeast of Mexico is similar to those reported previously in other Mexican regions and the most frequent risk factor continues being blood transfusion.


REFERENCES

  1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.

  2. Valdespino JL, Conde-González CJ, Olaiz-Fernández G, Palma O, Kershenobich D, Sepúlveda J. Seroprevalencia de la hepatitis C en adultos de México: ¿un problema de salud pública emergente? Salud Pública de México 2007; 49: s395-s403.

  3. Hernandez-Perez RE, Frias-Salcedo JA, Del Angel-Guevara O. [The seroprevalence of antibodies against the hepatitis C virus in blood donors at the Hospital Central Militar]. Salud Publica Mex 1994; 36: 538-40.

  4. Guerrero-Romero JF, Castaneda A, Rodriguez-Moran M. [Prevalence of risk factors associated with hepatitis C in blood donors in the municipality of Durango, Mexico]. Salud Publica Mex 1996; 38: 94-100.

  5. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999; 31 Suppl 1: 88-91.

  6. Vera de Leon L, Juarez Navarro JA, Diaz Gomez M, Mendez Navarro J, Chirino Sprung RA, Dehesa Violante M, Casillas Davila L, Rizo Robles MT, Torres Ibarra R, Cano Dominguez C, Nava Estrada J, Ramos Gomez M, Hernandez ME, Wong Gonzalez S, Felix Tamayo M, Corona Lechuga Mdel C, Zarate Negrete AR, Rangel Jimenez M, Rodriguez Hernandez H, Gonzalez Ortiz V, Tirado Estrella MP, Villanueva Carreto ML, Orta Flores R, Manteca Argumedo JL, Vazquez Avila I, Gonzalez Macias J, Razcon Hernandez O, Torres Lopez P, Bazan Perez C. [Epidemiologic and situational panorama of hepatitis C in Mexico]. Rev Gastroenterol Mex 2005; 70: 25-32.

  7. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.

  8. Mendez-Sanchez N, Motola-Kuba D, Zamora-Valdes D, Sanchez-Lara K, Ponciano-Rodriguez G, Uribe-Ramos MH, Vasquez-Fernandez F, Lezama-Mora J, Perez-Sosa JA, Baptista-Gonzalez HA, Uribe M. Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. Ann Hepatol 2006; 5: 276-80.

  9. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.

  10. Picchio GR, Nakatsuno M, Boggiano C, Sabbe R, Corti M, Daruich J, Perez-Bianco R, Tezanos-Pinto M, Kokka R, Wilber J, Mosier D. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophilic patients in the presence or absence of human immunodeficiency virus (HIV) co-infection. J Med Virol 1997; 52: 219-25.

  11. Oliveira ML, Bastos FI, Sabino RR, Paetzold U, Schreier E, Pauli G, Yoshida CF. Distribution of HCV genotypes among different exposure categories in Brazil. Braz J Med Biol Res 1999; 32: 279-82.

  12. Cital-Zamora JL, Navarrete-Castro R, Magana-Munoz KD, Martinez-Rodriguez ML, Calderon GM. Prevalence of hepatitis C virus genotypes in a Mexican population. Arch Med Res 2005; 36: 607.

  13. Sanchez-Avila JF, Gonzalez E, Vazquez V, Suarez S, Uribe M. Geographical distribution of HCV genotypes in Mexico. Ann Hepatol 2007; 6: 156-60.

  14. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.

  15. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121-7.

  16. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.

  17. Uribe M, Mendez-Sanchez N. [Hepatitis C in Mexico]. Rev Gastroenterol Mex 2002; 67 Suppl 2: S7-8.

  18. Rivas-Estilla AM, Ramirez-Valles E, Martinez-Hernandez R, Charles-Nino C, Ramirez-Camacho E, Rositas-Noriega F, Garza-Rodriguez ML, Barrera-Saldana HA, Trujillo-Murillo K, Ramos-Jimenez J. Hepatitis C virus infection among HIV-1 infected individuals from northern Mexico. Hepatol Res 2007; 37: 311-6.

  19. Vivas-Arceo C, Benavides SA, De Jesus Trujillo J, Panduro A, Rivas-Estilla AM. Hepatitis C virus: prevalence and routes of infection among blood donors of West Mexico. Hepatol Res 2003; 25: 115-123.




2020     |     www.medigraphic.com